Inversed, disproportionate contribution of fibrinogen to clot strength

TransfusionVolume 63, Issue 11 p. 2021-2022 TRANSFUSION MEDICINE ILLUSTRATED Inversed, disproportionate contribution of fibrinogen to clot strength Maggie M. Swift, Maggie M. Swift Department of Anesthesiology, McGovern Medical School at UT Health, Houston, Texas, USASearch for more papers by this authorJeffrey H. Fair, Jeffrey H. Fair Department of Surgery, McGovern Medical School at UT Health, Houston, Texas, USASearch for more papers by this authorEvan G. Pivalizza, Corresponding Author Evan G. Pivalizza [email protected] orcid.org/0000-0002-2543-2075 Department of Anesthesiology, McGovern Medical School at UT Health, Houston, Texas, USA Correspondence Evan G. Pivalizza, Department of Anesthesiology, McGovern Medical School at UT Health, MSB 5.020, 6431 Fannin St., Houston, TX 77030, USA. Email: [email protected]Search for more papers by this author Maggie M. Swift, Maggie M. Swift Department of Anesthesiology, McGovern Medical School at UT Health, Houston, Texas, USASearch for more papers by this authorJeffrey H. Fair, Jeffrey H. Fair Department of Surgery, McGovern Medical School at UT Health, Houston, Texas, USASearch for more papers by this authorEvan G. Pivalizza, Corresponding Author Evan G. Pivalizza [email protected] orcid.org/0000-0002-2543-2075 Department of Anesthesiology, McGovern Medical School at UT Health, Houston, Texas, USA Correspondence Evan G. Pivalizza, Department of Anesthesiology, McGovern Medical School at UT Health, MSB 5.020, 6431 Fannin St., Houston, TX 77030, USA. Email: [email protected]Search for more papers by this author First published: 29 September 2023 https://doi.org/10.1111/trf.17560Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. CONFLICT OF INTEREST STATEMENT Evan Pivalizza is a medical consultant for Lucid Lane, which offers on-line cognitive behavioral therapy to post-surgical patients who need assistance managing opioid medications and is a speaker for Haemonetics Corp, the manufacturer of the TEGR, as a clinical expert. Neither relationship has any contribution or conflict related to the current submission. Neither of the other authors has conflicts of interest to declare. REFERENCES 1Gäckler A, Rohn H, Lisman T, Benkö T, Witzke O, Kribben A, et al. Evaluation of hemostasis in patients with end-stage renal disease. PloS One. 2019; 14:e0212237. https://doi.org/10.1371/journal.pone.0212237 2Nunns GR, Moore EE, Chapman MP, Moore HB, Stettler GR, Peltz E, et al. The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. Am J Surg. 2017; 214: 1215–1218. https://doi.org/10.1016/j.amjsurg.2017.08.039 3Chapman MP, Moore EE, Burneikis D, Moore HB, Gonzalez E, Anderson KC, et al. Thrombelastographic pattern recognition in renal disease and trauma. J Surg Res. 2015; 194: 1–7. https://doi.org/10.1016/j.jss.2014.12.012 Volume63, Issue11November 2023Pages 2021-2022 ReferencesRelatedInformation